NOF Corporation Lifts FY2027 Forecast on Revenue Expansion Despite Margin Pressure
NOF Corporation (TSE:4403), a diversified Japanese specialty chemicals manufacturer, reported full-year FY2026 (ended March 2026) net profit growth of 11.1% to JPY 40.5bn, outpacing operating profit gains as non-operating income bolstered results. However, management’s cautious guidance for FY2027 signals concern over external headwinds, with operating profit growth projected to decelerate sharply despite a 23.7% revenue surge.
| Metric | FY2026 Actual | YoY Change |
|---|---|---|
| Revenue | JPY 258.0bn | +8.2% |
| Operating Profit | JPY 47.4bn | +4.6% |
| Ordinary Income | JPY 50.4bn | +8.1% |
| Net Profit | JPY 40.5bn | +11.1% |
| Operating Margin | 18.4% | — |
| Equity Ratio | 74.0% | (prev: 78.0%) |
Business Overview
NOF Corporation is a leading Japanese manufacturer of specialty lipid-based chemicals and functional compounds, with diversified operations spanning functional specialty products, pharmaceutical chemicals, life sciences, and drug delivery systems (DDS). The company’s portfolio spans industrial and pharmaceutical applications, positioning it in higher-margin segments of the chemical sector.
FY2026 Results: Profit Growth Outpaces Revenue
NOF’s full-year results reflect a divergence between top-line and bottom-line momentum. Revenue expanded 8.2% to JPY 258.0bn, yet operating profit rose only 4.6% to JPY 47.4bn—a compression that signals underlying cost pressures. The 18.4% operating margin, while robust in absolute terms, masks a deteriorating conversion rate: each percentage point of revenue growth yielded only 0.56 percentage points of operating profit growth.
This margin squeeze likely reflects elevated raw material costs and manufacturing pressures, a dynamic management explicitly flagged in forward guidance. Notably, net profit growth of 11.1% exceeded operating profit growth, driven by a 8.1% increase in ordinary income (keijo rieki, Japan’s recurring profit metric that includes non-operating income such as interest and dividend receipts). This divergence indicates that financial income and non-operating gains—potentially including foreign exchange benefits and investment revaluation—offset operational headwinds.
The equity ratio declined 4 percentage points to 74.0%, reflecting capital deployment through increased dividends (payout ratio rising from 29.2% to 34.6%) and growth investments. Operating cash flow surged 23.8% to JPY 35.9bn, demonstrating robust underlying cash generation despite profit margin compression. Capital expenditure moderated significantly, with investing cash outflows improving to JPY 4.4bn from JPY 13.7bn, suggesting the company has completed major capacity investments and is adopting a more selective capital allocation stance.
Next Year Guidance
| Metric | FY2027 Forecast | YoY Change |
|---|---|---|
| Revenue | JPY 319.0bn | +23.7% |
| Operating Profit | JPY 50.0bn | +5.5% |
| Ordinary Income | JPY 51.0bn | +1.3% |
| Net Profit | JPY 39.0bn | −3.8% |
Management’s FY2027 guidance reveals a markedly conservative posture. While revenue is projected to accelerate sharply to JPY 319.0bn (+23.7%), operating profit growth decelerates to just +5.5%—implying an operating margin compression to approximately 15.7%, down 270 basis points from FY2026. Net profit is forecast to decline 3.8% to JPY 39.0bn, with ordinary income growth stalling at +1.3%, suggesting management expects deteriorating non-operating income. These targets are decidedly conservative relative to the revenue growth trajectory, explicitly incorporating anticipated headwinds from U.S. trade policy uncertainty and global economic deceleration.
1. Margin Recovery Timing: The sharp operating margin compression embedded in FY2027 guidance (18.4% → 15.7%) is the critical variable. Management must demonstrate whether this reflects temporary cost inflation or structural competitive pressure. Quarterly results will signal whether margin stabilization emerges in H2 FY2027.
2. DDS and Life Sciences Contribution: With pharmaceutical and life sciences operations positioned as higher-margin growth drivers, investors should monitor segment performance to assess whether portfolio diversification is offsetting commodity chemical margin pressure.
3. Capital Allocation Discipline: The dividend payout ratio is projected to rise further to 41.3% in FY2027. Combined with moderating capex, this signals confidence in cash generation—but sustainability depends on whether operating profit can stabilize above current guidance assumptions amid external uncertainty.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.